Le rapport
Analyses approfondies du financement des entreprises, des stratégies de croissance et des insights de marché des entreprises les plus innovantes du monde
197 rapports et plus encore
Allogene Therapeutics raises $325M Series E at $3.9B valuation
Allogene Therapeutics raises $325M in Series E at $3.9B valuation. Allogeneic CAR T therapy developer...
Allogene Therapeutics Raises $325M in Series E
Allogene Therapeutics, a Biotech company based in 210 East Grand Avenue, South San Francisco, CA 94080, has raised $325M in Series E at a $3.9B valuation led by TPG, Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.
Arnatar Therapeutics raises $52M Series A
Arnatar Therapeutics raises $52M in Series A. Developing therapeutics for autoimmune and inflammatory diseases...
Denali Therapeutics raises $217M Series C at $5B valuation
Denali Therapeutics raises $217M in Series C at $5B valuation. Neurodegeneration therapeutics...
Strand Therapeutics raises $153M Series B
Strand Therapeutics raises $153M in Series B. mRNA-based therapeutics developer with novel cancer treatment platform...
Seres Therapeutics raises $113M Series E at $450M valuation
Seres Therapeutics raises $113M in Series E at $450M valuation. Microbiome therapeutic platform...
Crystalys Therapeutics raises $205M Series B at $900M valuation
Crystalys Therapeutics raises $205M in Series B at $900M valuation. Developing novel therapeutics for neurodegenerative diseases...
Kailera Therapeutics raises $400M Series A at $1.5B valuation
Kailera Therapeutics raises $400M in Series A at $1.5B valuation. Developing obesity therapeutics with acquired pipeline...
Expedition Therapeutics raises $165M Series B at $850M valuation
Expedition Therapeutics raises $165M in Series B at $850M valuation. Developing novel therapeutics for cardiometabolic diseases...
Affichage de 9 rapports • Page 1 • Catégorie : all
Restez en avance sur le marché
Recevez des insights hebdomadaires dans votre boîte de réception. Pas de spam, juste de l'intelligence.